Table 1.
Characteristics of the studies considered for reviewing the anti-inflammatory relationship response to curcumin supplementation in CKD and HD patients
| Study author | Year | Country | Gender | Age mean | N | Renal disorder | Total dose (per day) | Follow up | Intervention group mean±SD | Control group mean±SD |
|---|---|---|---|---|---|---|---|---|---|---|
| Interleukin 6 (IL-6) | ||||||||||
| Moreillon (Moreillon et al., 2013 ▶) | 2013 | USA | NA* | 56 | 16 | CKD** | 824 mg | 8 weeks | 35.5±46.7 | 30.7±46.7 |
| Samadian (Samadian et al., 2017 ▶) | 2017 | Iran | NA | 49 | 71 | HD*** | 1500 mg | 12 weeks | 5.73±5.16 | 35.37±53.59 |
| Vafadar-Afshar (Vafadar-Afshar et al., 2021 ▶) | 2021 | Iran | 62.97% male 37.03% female | 57 | 54 | HD | 120 mg | 12 weeks | 34.4±4.8 | 21.6±2.51 |
| Tumor necrosis factor α (TNF-α) | ||||||||||
| Khajehdehi (Khajehdehi et al., 2011 ▶) | 2011 | Iran | 55% male and 45% female | 52 | 40 | CKD | 1500 mg | 2 months | 12.8±2.9 | 18.4±24.1 |
| Moreillon (Moreillon et al., 2013 ▶) | 2013 | USA | NA | 56 | 16 | CKD | 824 mg | 8 weeks | 31.4±43.5 | 34.4±40.5 |
| Pakfetrat (Pakfetrat et al., 2014 ▶) | 2014 | Iran | 60% male and 40% female | 53 | 100 | HD | 1500 mg | 8 weeks | 36.36±42.38 | 84.11±65.14 |
| Vafadar-Afshar (Vafadar-Afshar et al., 2021 ▶) | 2021 | Iran | 62.97% male 37.03% female | 57 | 54 | HD | 120 mg | 12 weeks | 43.4±6.79 | 27.8±3.05 |
| High-sensitivity C-reactive protein (hs-CRP) | ||||||||||
| Moreillon (Moreillon et al., 2013 ▶) | 2013 | USA | NA | 56 | 16 | CKD | 824 mg | 8 weeks | 2±1 | 3±2 |
| Pakfetrat (Pakfetrat et al., 2014 ▶) | 2014 | Iran | 60% male and 40% female | 53 | 100 | HD | 1500 mg | 8 weeks | 10.8±9.7 | 7±8.9 |
| Samadian (Samadian et al., 2017 ▶) | 2017 | Iran | NA | 49 | 71 | HD | 1500 mg | 12 weeks | 1.23±82.3 | 53±4.2 |
| Kabodan (Kabodan et al., 2018 ▶) | 2018 | Iran | NA | NA | 64 | HD | 800 mg | 8 weeks | 22.1±37 | 19±26.76 |
| Alvarenga (L. Alvarenga et al., 2020 ▶) | 2020 | Brazil | NA | NA | 28 | HD | 2500 mg | 12 weeks | 3.8±2.15 | 2±1.35 |
| Shafabakhsh (Shafabakhsh et al., 2020 ▶) | 2020 | Iran | 60.4% male 39.6% female | 57 | 53 | HD | 80 mg | 12 weeks | 5.4±2.5 | 4.5±2 |
| Vafadar-Afshar (Vafadar Afshar et al., 2020 ▶) | 2020 | Iran | 62.97% male 37.03% female | 57 | 54 | HD | 120 mg | 12 weeks | 13±8.5 | 6.9±3.58 |
| Rodrigues (Rodrigues et al., 2021 ▶) | 2021 | Brazil | 67.45% male 32.55% female | 53 | 43 | HD | 1000 mg | 12 weeks | 5.2±8.5 | 5.6±8.5 |
* NA; Not applicable, **CKD; Chronic kidney disease, ***HD; Hemodialysis